Chitosan Wound Dressing for Antibiotic-Resistant Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical treatments lack effective solutions for antimicrobial infections, particularly those resistant to antibiotics, and require additional antimicrobial substances in wound dressings, which can complicate hygiene and efficacy.
Innovation Solution
A pharmaceutical composition comprising chitosan with a low degree of acetylation, used as an antimicrobial treatment and epithelial cell growth stimulant, providing a simultaneous antimicrobial and wound healing effect without the need for additional antimicrobial substances in wound dressings.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If additional antimicrobial substances are added to wound dressings to treat resistant infections, then antimicrobial efficacy is improved, but device complexity and hygiene management worsen
Solution Approach 1:
Chitosan serves multiple functions simultaneously: it provides antimicrobial activity against resistant bacteria, promotes epithelial cell growth, and maintains wound bed moisture balance. This multi-functionality eliminates the need for separate antimicrobial agents and growth factors, simplifying the dressing composition while maintaining comprehensive therapeutic efficacy
Solution Approach 2:
The patent specifies chitosan with a degree of acetylation of 0-60% and molecular weight of 1,000-1,000,000 Da, where low molecular weight chitosan (1,000-100,000 Da) provides superior antimicrobial activity. By optimizing these parameters, the invention achieves high antimicrobial efficacy with a single substance rather than requiring multiple additives
2Reliability
If multiple antimicrobial substances are used in wound dressings, then broad-spectrum antimicrobial coverage is improved, but ease of operation and hygiene management worsen
Solution Approach 1:
Chitosan exhibits broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, fungi, and viruses through its cationic polysaccharide structure that disrupts microbial cell membranes. This single substance replaces multiple specialized antimicrobials, simplifying hygiene protocols while maintaining comprehensive pathogen coverage
Solution Approach 2:
The patent addresses antibiotic-resistant bacteria by using chitosan, a natural polysaccharide that kills bacteria through physical membrane disruption rather than chemical inhibition. This converts the problem of antibiotic resistance into an opportunity to use a substance with inherently different, non-resistance-inducing mechanism of action
3Reliability
If chitosan with low degree of acetylation is used, then antimicrobial activity is improved, but solubility and ease of manufacture worsen
Solution Approach 1:
The patent specifies chitosan with degree of acetylation of 0-60% and molecular weight of 1,000-1,000,000 Da, where low molecular weight chitosan (1,000-100,000 Da) provides superior antimicrobial activity. By optimizing these parameters, the invention achieves high antimicrobial efficacy with a single substance rather than requiring multiple additives
Solution Approach 2:
The patent employs carriers or complexes to deliver chitosan to the wound site, improving solubility and handling properties during manufacturing and application. This intermediary approach allows low-degree-acetylation chitosan to maintain its high antimicrobial activity while becoming more manageable in processing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chitosan composition effectively treats microbial infections, including antibiotic-resistant strains, and promotes epithelial cell growth, maintaining wound dressing sterility and reducing microbial load, while minimizing systemic side effects.
Implementation Method 1
A first mechanism discussed involves an interaction with the cell surface of gram-negative bacteria, which interaction is believed to prevent the transport of essential solutes.
Implementation Method 2
Another mechanism involves an inhibition of RNA and protein synthesis in the cell nucleus.
Implementation Method 3
Other suggested mechanisms involve the activity of chitosan as a chelating agent
Implementation Method 4
chitosan's activity to interact with flocculate proteins
Implementation Method 5
a direct disturbance of membrane function in fungi
Implementation Method 6
chitosan for an epithelial cell growth stimulating treatment of a patient's tissue
Data Source
AI summary
A chitosan for use in an antimicrobial treatment of a patient's tissue and a pharmaceutical composition comprising a chitosan for use in an antimicrobial treatment of a patient's tissue. A method of treating a microbial infection, the method comprising the step of administering to a patient an effective amount of a chitosan and an aqueous solution comprising chitosan. A chitosan or a pharmaceutical composition comprising a chitosan for use in an epithelial cell growth stimulating treatment of a patient's tissue. A method of stimulating the growth of epithelial cells the method comprising the step of administering to a patient or to an epithelial cells containing cell culture an effective amount of a chitosan or a pharmaceutical composition comprising chitosan. A tissue dressing material characterized in that it consists of chitosan or a chitosan comprising composition.